From Reuters | EU regulators are expected to approve Abbott’s deal to buy French pharmaceutical company Solvay’s drug unit. Abbot- and Solvay currently co-markets two cholesterol treatments — Tricor and TriLipix.
Read full story: reuters.com
Filed under Pharmaceuticals
Abbott-Solvay deal expected to get EU OK
Posted Feb. 8, 2010 at 12:32 p.m.
I don’t usually reply to posts but I will in this case, great info…I will bookmark your site. Keep up the good work!